Abstract:Objective: To evaluate the five-year safety and efficacy of the second generation biodegradable polymer sirolimus-eluting stent (EXCROSSAL) in treating patients with de novo coronary artery diseases. Methods: Patients with coronary artery disease (CAD)who were implanted with EXTROSSAL stents in CREDIT Ⅱ and CREDIT Ⅲ study were included. CREDIT Ⅱ was a randomized trial, and CREDIT Ⅲ was a single-arm study. From November 2013 to December 2014, 833 CAD patients with de novo coronary lesions implanted with EXTROSSAL stents were selected from 33 centers in China. The primary outcome was 5-year target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction and clinically indicated target lesion revascularization. Secondary endpoints was patient-oriented composite endpoint (PoCE), including all-cause death, all myocardial infarction, or any revascularization within 5 years post stenting and stent thrombosis according to Academic Research Consortium's (ARC) definition. Kaplan Meier method was used to calculate the incidence of TLF and PoCE within 5 years after operation. Univariate Cox regression analysis was used to analyze the impacts of diabetes, small vessel disease (vessel diameter ≤ 2.74 mm), lesion length ≥ 16.7 mm and multivessel disease on the incidence of TLF within 5 years after operation. Results: A total of 833 patients were included in this study including 579 males (69.5%), the age was (59.3±9.1) years. And 832 (99.9%) patients completed 5-year clinical follow-up. The incidence of TLF and PoCE in the 5-year follow-up were 10.6%(86/811) and 15.5%(126/811), respectively. Stent thrombosis occurred in 1.0%(8/811) of patients. Univariate Cox regression analysis showed that vessel diameter ≤ 2.74 mm (HR=3.20,95%CI 1.90-5.39,P<0.001), lesion length ≥ 16.7 mm (HR=1.88,95%CI 1.18-2.99,P=0.007) and multivessel disease (HR=2.44,95%CI 1.60-3.72,P<0.001) were related factors of TLF within 5 years after operation. Conclusion: EXCROSSAL stent is effective and safe in treating CAD patients with de novo coronary lesions, with low incidence of TLF and PoCE within 5 years after operation.

Efficacy and Safety of A Second Generation Biodegradable-Polymer Sirolimus-Eluting Stent: One Year Results of The CREDIT 2 Trial.

First‐in‐man Study Evaluating the Safety and Efficacy of a Second Generation Biodegradable Polymer Sirolimus‐eluting Stent in the Treatment of Patients with De Novo Coronary Lesions: Clinical, Angiographic, and OCT Outcomes of CREDIT‐1

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Efficacy and Safety of a Biodegradable Polymer Cobalt-Chromium Sirolimus-Eluting Stent (EXCEL2) in Treating De Novo Coronary Artery Disease: A Pooled Analysis of the CREDIT II and CREDIT III Trials. DOI: 10.1002/ccd.26887

Real Polymer-Free Sirolimus- and Probucol-Eluting Versus Biodegradable Polymer Sirolimus-Eluting Stents for Obstructive Coronary Artery Disease: Dkplus-Wave 1, A Multi-Center, Randomized, Prospective Trial

Safety and efficacy of the second generation biodegradable polymer Cobalt-Chromium sirolimus-eluting stent (EXCEL 2) stent in diabetic patients:A Subgroup analysis of the CREDIT Ⅱ and CREDIT Ⅲ trials

Biolimus-coated Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis (BIO ASCEND ISR): a Randomised, Non-Inferiority Trial.

Long‐term Clinical, Angiographic, and Intravascular Ultrasound Outcomes of Biodegradable Polymer‐coated Sirolimus‐eluting Stents

A randomized comparison of healing response of the BuMA Supreme stent and Xience stent at one- and two-month follow-up: PIONEER-II OCT randomized controlled trial.

Safety And Efficacy Of Biodegradable-Polymer Coated Sirolimus-Eluting Stents In Real-World Practice: 18-Month Clinical And 9-Month Angiographic Outcomes

Randomized Clinical Trial Comparing Abluminal Biodegradable Polymer Sirolimus-Eluting Stents With Durable Polymer Sirolimus-Eluting Stents: Nine Months Angiographic And 5-Year Clinical Outcomes

Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.

A Randomized Comparison of Novel Biodegradable Polymer- and Durable Polymer-Coated Cobalt-Chromium Sirolimus-Eluting Stents.

Biodegradable polymer-coated versus durable polymer-coated sirolimus-eluting stents: the final 5-year outcomes of the I-LOVE-IT 2 trial

Five Years Sustained Clinical Safety and Efficacy of an Abluminal Biodegradable-Polymer Coated Sirolimus-Eluting Stent: A Randomized Controlled Trial

A New Generation of Biodegradable Polymer-Coated Sirolimus-Eluting Stents for the Treatment of Coronary Artery Disease: Final 5-Year Clinical Outcomes from the CREATE Study.

[Five-year clinical outcomes of the second generation biodegradable polymer sirolimus-eluting stent (EXCROSSAL) in treating patients with de novo coronary lesions]

TCT-568 Real Polymer-free Sirolimus- and Probucol-Eluting Versus Biodegradable Polymer Sirolimus-Eluting Stents for Obstructive Coronary Artery Disease: DKPLUS-Wave 1, a Multi-Center, Randomized, Prospective Trial

Novel Completed Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Sirolimus-Eluting Stent in De Novo Lesions: Nine-Month Angiographic and Three-Year Clinical Outcomes of Hope Trial

Long‐Term Clinical Outcomes of Biodegradable‐ Versus Durable‐Polymer‐Coated Everolimus‐Eluting Stents in Real‐World Post‐Marketing Study

Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in "real-world" practice: Three-year outcomes of the CREATE (multi-center registry of EXCEL biodegradable polymer drug eluting stents) study